Training the Immune Mind: Advancing Vaccine Design to Educate T Cells

Vaccines function as protective agents by priming the host’s immunity to recognize and respond to specific antigens derived from infectious pathogens or malignant cells (Pollard and Bijker  et al. 2021). By inducing both humoral (antibody-mediated) and cellular (T cell–mediated) immune responses, vaccines allow the immune system to mount a rapid and effective defense upon subsequent exposure. This immunological priming reduces disease severity and induces targeted immune responses against tumor-associated antigens or neoantigens in cancer immunotherapy.

To elicit an antigen-specific immune response, researchers have developed a variety of vaccine platforms, each offering distinct advantages depending on their composition and means of delivery. These platforms include live-attenuated or inactivated pathogens, purified microbial or tumor-associated proteins, and nucleic acid-based technologies such as mRNA vaccines. Each approach is designed with specific disease targets and varies in terms of immunogenicity, safety, and stability. For instance, mRNA vaccines, first widely used during the COVID-19 pandemic, allow fast development and stimulate a broad and robust immune activation, making them well-suited for emerging infectious diseases.

Many vaccines incorporate adjuvants — substances that enhance the immune response to the target antigen. One of the most commonly used adjuvants is aluminum-based compounds (e.g., alum), which are well-documented for their ability to augment antibody production and prolong immunological memory. The inclusion of adjuvants is particularly critical in vaccines formulated with purified proteins, as these components often exhibit limited immunogenicity when administered alone.

The primary goal of vaccination is to induce durable adaptive immune responses and establish long-term immunological memory. While many vaccines confer effective protection at the individual level, some fail to generate potent or sustained immunity. This limitation prompts the need for improved design and optimization of vaccine formulations to enhance their immunogenicity and clinical efficacy.

In this blog, we will discuss the role of T cells in the vaccine-induced immune response and the key challenges in achieving long-lasting and broad-spectrum immunity.

What Is the Function of T Cells in Vaccine-Induced Immunity?

T cells play a critical role in vaccine-induced immunity by orchestrating cellular immune responses that complement and enhance humoral immunity. Following vaccination, antigen-presenting cells (APCs) like dendritic cells process and present vaccine-derived antigens through major histocompatibility complex (MHC) class I and class II pathways. This antigen presentation subsequently activates naïve CD8⁺ and CD4⁺ T cells, leading to clonal expansion and functional differentiation into effector T cells.

Among CD4⁺ T cells, a specialized T cell population known as T follicular helper (T_fh) cells is crucial for promoting B cell maturation and antibody production through CD40L engagement and the secretion of cytokines such as IL-21 (Gattinoni et al. 2017).

In addition, CD8⁺ cytotoxic T lymphocytes (CTLs) acquire the ability to recognize and eliminate infected or malignant cells displaying antigens via MHC class I molecules.

Following the peak of the expansion phase, most effector T cells undergo apoptosis during the contraction phase. However, a portion of these T cells persists and differentiates into distinct subsets of memory T cells that provide long-term immune protection.

Central memory T cells (T_CM), marked by high expression of CCR7 and CD62L in humans, circulate through secondary lymphoid organs (e.g., lymph nodes) and retain the ability to proliferate upon re-exposure to antigen.

Effector memory T cells (T_EM), marked by low CCR7 and CD62L expression in humans, migrate through peripheral tissues and can rapidly carry out effector functions.

Tissue-resident memory T cells (T_RM), which express CD69 and CD103, remain within non-lymphoid tissues (e.g., the skin), where they trigger swift local immune responses at the site of initial infection.

Together, these memory T cell populations enable the immune system to mount faster and more effective responses upon subsequent encounters with the same pathogen or antigen, contributing to the durable and protective immunity established by vaccination.

Enhancing Cell-Mediated Immunity: Challenges and Innovations in Vaccine Development

A major challenge in vaccine development is increasing the production of stem-like memory CD8+ T cells (T_SCM), marked by high expression of TCF-1. T_SCM have self-renewing capacity and can give rise to central memory T cells (T_CM).

A recent study by Broomfield et al. (2025) demonstrates that early blockade of type I interferon (IFN-I) signaling during infection or mRNA vaccination enhances T_SCM differentiation and the vaccine-induced immune response (Broomfield et al. 2025). Using the lymphocytic choriomeningitis virus (LCMV) as a chronic infection model, the researchers show that transient inhibition of IFN-I responses improves CD8+ T cell immunity by promoting the transition of precursor exhausted T cells (T_PEX) into T_SCM. This shift is driven by changes in the localization of T cells in lymph nodes and altered chemokine expression (e.g., CXCR3). The findings suggest that modulating early antiviral signaling can promote long-term immune memory and improve vaccine protection against chronic infections.

Another major challenge in optimizing vaccine design is the choice of adjuvants. While adjuvants are well known to enhance immunogenicity following vaccination, the precise mechanisms underlying immune activation remain incompletely understood. Previous studies have shown that certain adjuvants can strongly influence T cell responses. In particular, Toll-like receptor (TLR) ligands such as CpG (TLR9 ligand) and MPL (TLR4 ligand) have been found to induce robust T_fh cell responses with high-affinity T cell receptor (TCR) repertoires, in contrast to non-TLR-based adjuvants such as alum (Li et al. 2024, Malherbe et al. 2008).

However, how these adjuvants modulate different subsets of memory T cells remains an open question. Moreover, whether these immunological effects also depend on the type of antigen used in the vaccine is not yet known.

Future Directions in Vaccine Design

In summary, while substantial progress has been made in harnessing T cell immunity for vaccine development, several complex challenges remain. For instance, both antigenic diversity and immune imprinting — where the immune system preferentially recalls earlier responses — can reduce vaccine effectiveness against emerging pathogen variants. These issues will not only limit the breadth and durability of vaccine-induced protection but also highlight the need for continued research into cell-mediated immunity and improved adjuvant systems to guide the design of next-generation vaccines for infectious diseases and cancer.